Alshamsi and Mousa work within the Biomedical Science and Discovery (BISDI) Program—a strategic collaboration between Khalifa University and VIB–KU Leuven—to develop novel immunotherapies for diabetes. Using in-house AI tools, they identify mystery genes that cause endothelial cell dysfunction, which drives vascular complications such as heart attacks, strokes, and vision loss. They have co-authored papers in leading scientific journals including nature and ScienceDirect.